# The Effectiveness of Traditional Chinese Medicine in Treating Patients with Leukemia

Authors: Yu-Jun Wang; Chung-Chih Liao; Hsuan-Ju Chen; Ching-Liang Hsieh; Tsai-Chung Li
Journal: Evidence-Based Complementary and Alternative Medicine
 (2016)

---

## Abstract

Leukemia is the most common malignancy among all childhood cancers and is associated with a low survival rate in adult patients. Since 1995, the National Health Insurance (NHI) program in Taiwan has been offering insurance coverage for Traditional Chinese Medicine (TCM), along with conventional Western medicine (WM). This study analyzes the status of TCM utilization in Taiwan, in both pediatric and adult patients with leukemia. A retrospective cohort study was conducted using population-based National Health Insurance Research Database of Registry of Catastrophic Illness, involving patient data from 2001 to 2010 and follow-up data through 2011. The effectiveness of TCM use was evaluated. Relevant sociodemographic data showed that both pediatric and adult patients who were TCM users one year prior to leukemia diagnosis were more likely to utilize TCM services for cancer therapy. A greater part of medical expenditure of TCM users was lower than that of TCM nonusers, except little discrepancy in drug fee of adult patients. The survival rate is also higher in TCM users. Altogether, these data show that TCM has the potential to serve as an adjuvant therapy when combined with conventional WM in the treatment of patients with leukemia.


---

## Body

## 1. Introduction

Leukemia originates in the bone marrow and results in the production of a large number of abnormal white blood cells. The four main subtypes of leukemia are acute lymphoblastic leukemia (ALL), acute myelogenous leukemia (AML), chronic lymphocytic leukemia (CLL), and chronic myelogenous leukemia (CML) [1]. Leukemia is the most common malignancy diagnosed in children accounting for greater than 30% of all childhood cancers [2]. While ALL is the most prevalent cancer in childhood and also the first leading cause of death from cancer within 20 years of age [3], AML is more common in older adults [4]. Patients with leukemia may undergo chemotherapy or hematopoietic stem cell transplants, which are associated with massive physical suffering and economic burden [5, 6].The National Health Insurance (NHI) program has offered insurance cover for Traditional Chinese Medicine (TCM) and conventional Western medicine (WM) since 1995. Several studies have demonstrated that TCM as adjuvant therapy can help improve the quality of life and alleviate the side effects associated with WM use. Importantly, it can enhance the efficacy of WM treatment against tumors and improve the survival rate [7–13]. For instance, one study indicated that TCM combined with chemotherapy significantly elevates survival rate and improves the quality of life in patients with advanced non-small-cell lung carcinoma [12]. Another observational study demonstrated that TCM as adjuvant therapy helps to lower the risk of mortality relative to “TCM nonusers” in advanced breast cancer [9]. Apart from case reports and standardized questionnaire surveys, there are few large-scale studies on TCM use among leukemia patients [14, 15]. Thus, our study aimed to explore the determinants of TCM utilization in both pediatric and adult leukemia patients and further evaluate the overall survival of patients.


## 2. Materials and Methods

### 2.1. Research Data Sources

The NHI program, initiated in 1995, currently covers nearly 99.6% of the residents in Taiwan. The Bureau of National Health Insurance has contracts and cooperative agreements with nearly 97% of all hospitals and 92% of all clinics. This study included National Health Insurance Research Database (NHIRD) claim datasets that are safe from counterfeits due to the severe penalties involved [16]. The NHIRD datasets used in this study consisted of registry for beneficiaries, ambulatory and inpatient care claims, and registry for catastrophic illness from 1999 to 2011. Besides these, the NHIRD database contains demographic data, dates of visits, International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) diagnostic codes, complete prescription details, and expenditure incurred by the beneficiaries. Data for detailed diagnoses and treatments provided by physicians were included. On the other hand, all cancer cases registered in the catastrophic illness database were eligible for an exemption from copayment. Our study was approved by the Joint Institutional Review Board of Public Health, Social and Behavioral Science Committee, China Medical University and Hospital.


### 2.2. Study Population

Our population-based retrospective cohort study included newly diagnosed patients with leukemia (ICD-9-CM code 204–208) identified from the registry of catastrophic illness between January 1, 2001, and December 31, 2010. In Taiwan health care system, the diagnosis of leukemia cases was done by WM physicians and cannot be done by TCM physicians because all diagnosis tests, including regular blood routine test (CBC/DC), blood smear (observing blood cell morphology), bone marrow biopsy (observing bone marrow cell morphology), and symptoms and signs, can be performed only by WM physicians. The index date was the initial date of leukemia diagnosis and all patients were followed up through December 31, 2011, or until the patients’ death date within this interval or withdrawal from NHI. The index date was the date of first diagnosis. We analyzed 2,355 newly diagnosed pediatric patients (0–18 years old) and 10,208 newly diagnosed adult patients (19–80 years old) with leukemia. Patients who visited TCM physicians and used TCM at least once after being diagnosed with leukemia were deemed “TCM users” and the rest were deemed “TCM nonusers.”


### 2.3. Comorbidities and Classification of Expenditures

This study considered TCM and WM ambulatory care, including dates of visit, date of birth, patient gender, medical facility and department visited, prescribing physician, dispensing pharmacist, three items from the ICD-9-CM codes, primary procedure, type of copayment, and paid amounts. We also analyzed the coexisting diseases in the leukemia patients based on the ICD-9-CM codes. Types of expenditure included fees for consultation, treatment and medical supplies, diagnosis fee, and drug fee.


### 2.4. Sociodemographic Factors and Urbanization Levels of Residential Area

The sociodemographic factors included age, gender, insurance premium amount, and the insured unit. Pediatric patients were further divided into 3 subgroups: 0–6, 7–12, and 13–18 years. Similarly, the adult patients were also divided into 3 subgroups: 19–40, 41–60, and 61–80 years. The amount of insurance premium, determined from the individual working salary, was classified into four levels: <20,000, 20,000–39,999, 40,000–59,999, and >60,000 NT$/month. The residential areas of the study population comprised 6 areas: Northern area, Taipei, Central area, Southern area, Eastern area, and Kao-Ping area (Figure1). Furthermore, the urbanization level of the townships in Taiwan was categorized according to educational level of the population, population density, the ratio of elder people, and occupation in general [17]. The insured unit included government, school, private enterprise, occupational member, farmer and fishermen, low-income household, and veterans.Figure 1
The residential areas of the study population.


### 2.5. Statistical Analysis

All analyses were performed separately for the pediatric and adult patient groups. The continuous variables were evaluated using means, standard deviations, and 95% confidence interval (CI), whereas categorical variables were evaluated using the numbers, percentages, and 95% CI. To compare the differences in continuous variables between TCM users and nonusers, Student’st-test was used, whereas Chi-square test was used to analyze the categorical variables. Furthermore, the adjusted odds ratio (OR), calculated using a multivariate logistic regression analysis, was used to explore the determinants of TCM utilization. The Kaplan-Meier estimator with a log-rank test was applied to evaluate the effect of TCM use on overall survival. Pairwise comparisons of overall survival among groups of no, low, and high TCM use were adjusted by Bonferroni correction. All p values were calculated using two-sided tests, and the threshold for statistical significance was set at p<0.05. All analyses were performed using Statistical Analysis System (SAS) version 9.3 (SAS Institute Inc., Cary, NC, USA).


## 2.1. Research Data Sources

The NHI program, initiated in 1995, currently covers nearly 99.6% of the residents in Taiwan. The Bureau of National Health Insurance has contracts and cooperative agreements with nearly 97% of all hospitals and 92% of all clinics. This study included National Health Insurance Research Database (NHIRD) claim datasets that are safe from counterfeits due to the severe penalties involved [16]. The NHIRD datasets used in this study consisted of registry for beneficiaries, ambulatory and inpatient care claims, and registry for catastrophic illness from 1999 to 2011. Besides these, the NHIRD database contains demographic data, dates of visits, International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) diagnostic codes, complete prescription details, and expenditure incurred by the beneficiaries. Data for detailed diagnoses and treatments provided by physicians were included. On the other hand, all cancer cases registered in the catastrophic illness database were eligible for an exemption from copayment. Our study was approved by the Joint Institutional Review Board of Public Health, Social and Behavioral Science Committee, China Medical University and Hospital.


## 2.2. Study Population

Our population-based retrospective cohort study included newly diagnosed patients with leukemia (ICD-9-CM code 204–208) identified from the registry of catastrophic illness between January 1, 2001, and December 31, 2010. In Taiwan health care system, the diagnosis of leukemia cases was done by WM physicians and cannot be done by TCM physicians because all diagnosis tests, including regular blood routine test (CBC/DC), blood smear (observing blood cell morphology), bone marrow biopsy (observing bone marrow cell morphology), and symptoms and signs, can be performed only by WM physicians. The index date was the initial date of leukemia diagnosis and all patients were followed up through December 31, 2011, or until the patients’ death date within this interval or withdrawal from NHI. The index date was the date of first diagnosis. We analyzed 2,355 newly diagnosed pediatric patients (0–18 years old) and 10,208 newly diagnosed adult patients (19–80 years old) with leukemia. Patients who visited TCM physicians and used TCM at least once after being diagnosed with leukemia were deemed “TCM users” and the rest were deemed “TCM nonusers.”


## 2.3. Comorbidities and Classification of Expenditures

This study considered TCM and WM ambulatory care, including dates of visit, date of birth, patient gender, medical facility and department visited, prescribing physician, dispensing pharmacist, three items from the ICD-9-CM codes, primary procedure, type of copayment, and paid amounts. We also analyzed the coexisting diseases in the leukemia patients based on the ICD-9-CM codes. Types of expenditure included fees for consultation, treatment and medical supplies, diagnosis fee, and drug fee.


## 2.4. Sociodemographic Factors and Urbanization Levels of Residential Area

The sociodemographic factors included age, gender, insurance premium amount, and the insured unit. Pediatric patients were further divided into 3 subgroups: 0–6, 7–12, and 13–18 years. Similarly, the adult patients were also divided into 3 subgroups: 19–40, 41–60, and 61–80 years. The amount of insurance premium, determined from the individual working salary, was classified into four levels: <20,000, 20,000–39,999, 40,000–59,999, and >60,000 NT$/month. The residential areas of the study population comprised 6 areas: Northern area, Taipei, Central area, Southern area, Eastern area, and Kao-Ping area (Figure1). Furthermore, the urbanization level of the townships in Taiwan was categorized according to educational level of the population, population density, the ratio of elder people, and occupation in general [17]. The insured unit included government, school, private enterprise, occupational member, farmer and fishermen, low-income household, and veterans.Figure 1
The residential areas of the study population.


## 2.5. Statistical Analysis

All analyses were performed separately for the pediatric and adult patient groups. The continuous variables were evaluated using means, standard deviations, and 95% confidence interval (CI), whereas categorical variables were evaluated using the numbers, percentages, and 95% CI. To compare the differences in continuous variables between TCM users and nonusers, Student’st-test was used, whereas Chi-square test was used to analyze the categorical variables. Furthermore, the adjusted odds ratio (OR), calculated using a multivariate logistic regression analysis, was used to explore the determinants of TCM utilization. The Kaplan-Meier estimator with a log-rank test was applied to evaluate the effect of TCM use on overall survival. Pairwise comparisons of overall survival among groups of no, low, and high TCM use were adjusted by Bonferroni correction. All p values were calculated using two-sided tests, and the threshold for statistical significance was set at p<0.05. All analyses were performed using Statistical Analysis System (SAS) version 9.3 (SAS Institute Inc., Cary, NC, USA).


## 3. Results

### 3.1. Factors Associated with TCM Use

A total of 292 (12.40%) pediatric patients and 936 (9.17%) adult patients availed TCM outpatient services. In these leukemia patients, we observed that patients who were TCM users one year prior to the leukemia diagnosis and who resided in central area were more likely to utilize TCM services (Table1). The mean numbers of days taking TCM in pediatric and adult leukemia patients were 184 (SD = 328) days and 107 (SD = 254) days, respectively. The mean outpatient department (OPD) visits for TCM in pediatric and adult leukemia patients were 20.3 (SD = 35.3) and 10.5 (SD = 22.8), respectively. The distributions of cancer type were similar between TCM users and nonusers in both pediatric and adult leukemia patients.Table 1
Sociodemographic factors of pediatric and adult patients with leukemia according to use of TCM.
Characteristic ⁢Pediatric (N=2,355) ⁢Adult (N=10,208) TCM users TCM nonusers Adjusted OR‡ (95% CI) TCM users TCM nonusers Adjusted OR‡ (95% CI) N % N % N % N % Number of patients 292  2,063   936  9,272 Age, years 0–6 139 47.60 1,016 49.25 1.00 7–12 89 30.48 480 23.27 1.10 (0.81–1.50) 13–18 64 21.92 567 27.48 0.64 (0.46–0.89)∗∗ 19–40      274 29.27 2,199 23.72 1.00 41–60      379 40.38 3,012 32.48 0.95 (0.80–1.13) 61–80      284 30.34 4,061 43.80 0.60 (0.48–0.70)∗∗∗ Means (SD) 8.03 (5.07) 8.41 (5.65)  51.26 (15.67) 55.39 (17.24) Gender Female 129 44.18 843 40.86 1.00 428 45.73 3,740 40.34 1.00 Male 163 55.82 1,220 59.14 0.83 (0.64–1.07) 508 54.27 5,532 59.66 0.86 (0.74–0.99)∗ TCM use one year prior to leukemia diagnosis TCM nonusers 180 61.64 1,523 73.82 1.00 437 46.69 6,048 65.23 1.00 TCM users 112 38.36 540 26.18 1.62 (1.23–2.13)∗∗∗ 499 53.31 3,224 34.77 1.97 (1.71–2.26)∗∗∗ Insured amount (NT$/month) <20,000 286 97.95 2,035 98.64 1.00 610 65.17 6,736 72.65 1.00 20,000–39,999 6 2.05 27 1.31 2.02 (0.79–5.15) 197 21.05 1,613 17.40 1.23 (1.02–1.47)∗ 40,000–59,999 0 0.00 1 0.05 — 101 10.79 735 7.93 1.48 (1.15–1.90)∗∗ ≥60,000 — — — — — 28 2.99 188 2.03 1.65 (1.08–2.55)∗ Urbanization Level 1 (highest) 78 26.71 564 27.34 1.00 278 29.70 2,521 27.19 1.00 Level 2 97 33.22 655 31.75 0.85 (0.59–1.24) 279 29.81 2,698 29.10 0.86 (0.70–1.04) Level 3 48 16.44 371 17.98 0.52 (0.32–0.82)∗∗ 149 15.92 1,625 17.53 0.67 (0.53–0.85)∗∗∗ Level 4 45 15.41 296 14.35 0.63 (0.39–1.02) 134 14.32 1,329 14.34 0.74 (0.58–0.96)∗ Level 5 (lowest) 24 8.22 177 8.58 0.63 (0.34–1.14) 96 10.26 1,098 11.84 0.69 (0.51–0.94)∗ Residential area Northern 32 10.96 304 14.74 1.00 85 9.08 1,245 13.43 1.00 Taipei 75 25.68 750 36.35 0.76 (0.46–1.24) 274 29.27 229 34.83 1.01 (0.77–1.34) Central 104 35.62 306 14.83 3.33 (2.12–5.23)∗∗∗ 265 28.31 1,623 17.51 2.41 (1.85–3.14)∗∗∗ Southern 36 12.33 324 15.71 1.17 (0.69–1.99) 163 17.41 1,372 14.80 1.95 (1.47–2.59)∗∗∗ Eastern 3 1.03 42 2.04 0.73 (0.21–2.58) 27 2.88 261 2.82 1.78 (1.11–2.84)∗ Kao-Ping 42 14.38 337 16.34 1.16 (0.70–1.92) 122 13.03 1,541 16.62 1.13 (0.84–1.52) Insured unit Government, school employees 39 13.59 176 9.30 1.00 130 13.92 1,056 11.42 1.00 Private enterprise employees 145 50.52 916 48.39 0.70 (0.47–1.05) 404 43.25 3,533 38.21 0.91 (0.73–1.13) Occupational member 37 12.89 342 18.07 0.47 (0.28–0.77)∗∗ 198 21.20 1,973 21.34 0.87 (0.68–1.12) Farmers, fishermen 36 12.54 226 11.94 0.69 (0.40–1.18) 141 15.10 1,827 19.76 0.80 (0.60–1.07) Low-income households and veterans registered in local government agency 30 10.45 233 12.31 0.58 (0.34–0.98) 61 6.53 857 9.27 0.73 (0.52–1.02) Number of days taking TCM, means (SD) 184 (328) — —  107 (254) — — OPD visits for TCM, means (SD) 20.3 (35.3) — —  10.5 (22.8) — — Cancer subtype Lymphoid leukemia 205 70.21 1,377 66.75 1.00 217 23.18 1,896 20.45 1.00 Myeloid leukemia 79 27.05 609 29.52 1.10 (0.83–1.44) 649 69.34 6,670 71.94 0.85 (0.72–1.00) Uncertain 8 2.74 77 3.73 0.88 (0.42–1.85) 70 7.48 706 7.61 0.87 (0.65–1.15) ICD-9-CM: lymphoid leukemia, 204.xx; myeloid leukemia, 205.xx. TCM: Traditional Chinese Medicine; OR: odd ratio; SD: standard deviation; CI: confidence interval; OPD: outpatient department. ⁢p∗<0.05, p∗∗<0.01, and p∗∗∗<0.001. ‡Adjusted ORs were from the model considering age, gender, visit one year ago, insured amount, urbanization, residential area, and insured unit.


### 3.2. Medical Institutes

TCM users within pediatric leukemia patients engaged private hospitals more often for outpatient services than TCM pediatric nonusers (42.15% versus 38.70%). Similar trend was also seen within adult leukemia patients (36.17% versus 34.20%). On the contrary, private clinics were more often engaged for outpatient services by TCM nonusers of pediatric patients when compared to TCM users (41.37% versus 35.22%) as well as by TCM adult nonusers (43.32% versus 41.13%) (Table2).Table 2
Distributions of outpatient service providers for pediatric and adult patients with leukemia during 2001–2011.
Outpatient services providers TCM users TCM nonusers p value for χ2 Visits Percentage (95% CI) Visits Percentage (95% CI) Pediatric Type of provider     <0.001 Public hospitals 20,407 22.33 (22.06, 22.6) 80,522 19.47 (19.35, 19.59) Public Chinese medicine hospitals 20 0.02 (0.01, 0.03) 92 0.02 (0.02, 0.03) Private hospitals 38,522 42.15 (41.83, 42.47) 160,049 38.70 (38.55, 38.85) Private Chinese medicine hospitals 86 0.09 (0.07, 0.11) 191 0.05 (0.04, 0.05) Public clinics 160 0.18 (0.15, 0.2) 1,497 0.36 (0.34, 0.38) Private clinics 32,187 35.22 (34.91, 35.53) 171,108 41.37 (41.22, 41.52) Other medicine service providers 9 0.01 (0, 0.02) 103 0.02 (0.02, 0.03)  Total 91,391  413,562  Adult Type of provider     <0.001 Public hospitals 52,167 20.64 (20.49, 20.80) 354,202 19.77 (19.71, 19.83) Public Chinese medicine hospitals 400 0.16 (0.14, 0.17) 905 0.05 (0.05, 0.05) Private hospitals 91,396 36.17 (35.98, 36.36) 612,655 34.20 (34.13, 34.27) Private Chinese medicine hospitals 614 0.24 (0.22, 0.26) 4,044 0.23 (0.22, 0.23) Public clinics 3,782 1.5 (1.45, 1.54) 40,716 2.27 (2.25, 2.29) Private clinics 103,932 41.13 (40.94, 41.32) 776,052 43.32 (43.24, 43.39) Other medicine service providers 399 0.16 (0.14, 0.17) 3,026 0.17 (0.16, 0.17)  Total 252,690  1,791,600 TCM: Traditional Chinese Medicine; CI: confidence interval.


### 3.3. Coexisting Diseases

We observed that lymphoid leukemia and myeloid leukemia were the two major diagnoses in these leukemia patients. Lymphoid leukemia was common in children and myeloid leukemia was diagnosed mainly in adults. Acute upper and lower respiratory infections were commonly diagnosed in both pediatric and adult patients, irrespective of TCM use by the patients (Table3).Table 3
Top 5 disease codes among pediatric and adult leukemia patients during the years 2001–2011 for all outpatients visits.
Ranking TCM users TCM nonusers Disease (Code) Number Percentage (95% CI) Disease (Code) Number Percentage (95% CI) Pediatric Total visits 91,391   413,562 1 Lymphoid leukemia (204) 36,529 39.97 (39.65, 40.29) Lymphoid leukemia (204) 138,518 33.49 (33.35, 33.64) 2 Myeloid leukemia (205) 7,801 8.54 (8.35, 8.72) Acute upper respiratory infections (465) 45,756 11.06 (10.97, 11.16) 3 Acute upper respiratory infections (465) 6,873 7.52 (7.35, 7.69) Myeloid leukemia (205) 34,551 8.35 (8.27, 8.44) 4 Leukemia of unspecified cell type (208) 4,698 5.14 (5, 5.28) Acute bronchitis and bronchiolitis (466) 15,506 3.75 (3.69, 3.81) 5 Acute bronchitis and bronchiolitis (466) 2,962 3.24 (3.13, 3.36) Acute sinusitis (461) 12,141 2.94 (2.88, 2.99)  Adult Total visits 252,690   1,791,600 1 Myeloid leukemia (205) 55,031 21.78 (21.62, 21.94) Myeloid leukemia (205) 264,653 14.77 (14.72, 14.82) 2 Lymphoid leukemia (204) 19,336 7.65 (7.55, 7.76) Acute upper respiratory infections (465) 97,491 5.44 (5.41, 5.47) 3 Acute upper respiratory infections (465) 11,117 4.4 (4.32, 4.48) Lymphoid leukemia (204) 76,117 4.25 (4.22, 4.28) 4 Gingival and periodontal diseases (523) 5,680 2.25 (2.19, 2.31) Diabetes mellitus (250) 56,042 3.13 (3.1, 3.15) 5 Diseases of hard tissues of teeth (521) 5,123 2.03 (1.97, 2.08) Essential hypertension (401) 53,009 2.96 (2.93, 2.98) TCM: Traditional Chinese Medicine; CI: confidence interval.


### 3.4. Expenditures

According to our analysis, drug fee was the major component of all outpatient medical expenditures (Table4). For both pediatric and adult leukemia patients, the average cost of total amount per visit was higher for TCM users than that of TCM nonusers. In adult leukemia patients, the average cost of drug fee per visit in TCM users was higher than that of TCM nonusers. Nevertheless, the differences in average costs between these two groups were indeed minimal (2,557.98 NT$ versus 2,535.07 NT$). The costs of other items per visit in TCM users in adult leukemia patients were significantly lower than those of TCM nonusers, including fees for consultation, treatment, medical supply, and diagnosis fee. In pediatric patients, the average cost per visit in TCM users was consistently higher than that of TCM nonusers for all items including fees for consultation, treatment, medical supply, diagnosis fee, and drug fee.Table 4
Expenditures for outpatient services for pediatric and adult leukemia patients (NT$) during the period 2001–2011.
Characteristic TCM users TCM nonusers t value Total Percentage(95% CI) Average cost per visit(95% CI) Total Percentage(95% CI) Average cost per visit(95% CI) Pediatric Outpatient visits 91,391   413,562 Fees for consultation, treatment, and medical supplies 52,088,100 38.09 (38.08, 38.1) 569.95 (559.62, 580.28) 245,838,958 32.74 (32.73, 32.74) 594.45 (589.71, 599.19) 4.22 ∗ ∗ ∗ Diagnosis fee 19,341,052 14.14 (14.14, 14.15) 211.63 (210.86, 212.4) 88,180,707 11.74 (11.74, 11.74) 213.22 (212.84, 213.61) 3.64 ∗ ∗ ∗ Drug fee 65,311,809 47.76 (47.75, 47.77) 714.64 (680.14, 749.15) 416,969,010 55.52 (55.52, 55.53) 1008.25 (986.8, 1029.7) 14.16 ∗ ∗ ∗ Total amount 136,740,961 100 1496.22 (1459.61, 1532.83) 750,988,675 100 1815.92 (1793.74, 1838.1) 14.64 ∗ ∗ ∗  Adult Outpatient visits 252,690   1,791,600 Fees for consultation, treatment, and medical supplies 170,260,064 19.55 (19.55, 19.56) 673.79 (663.88, 683.70) 1,282,955,508 20.66 (20.66, 20.66) 716.10 (711.68, 720.52) 7.64 ∗ ∗ ∗ Diagnosis fee 54,059,202 6.21 (6.21, 6.21) 213.93 (213.46, 214.41) 386,270,204 6.22 (6.22, 6.22) 215.60 (215.42, 215.78) 6.46 ∗ ∗ ∗ Drug fee 646,375,253 74.24 (74.23, 74.24) 2557.98 (2512.05, 2603.91) 4,541,817,387 73.12 (73.12, 73.13) 2535.07 (2516.85, 2553.29) −0.91 Total amount 870,694,519 100 3445.70 (3398.59, 3492.81) 6,211,043,099 100 3466.77 (3447.99, 3485.55) 0.81 p   ∗ ∗ ∗ < 0.001.


### 3.5. Most Commonly Prescribed TCM Single and Formula Products

Details of the TCM single and formula products most frequently prescribed by TCM physicians are shown in Table5. In pediatric leukemia patients,Radix Astragali membranaceus was the most commonly prescribed TCM single product, followed byBulbus Fritillariae thunbergii, andHerba Hedyotis diffusa. Moreover, Xiang Sha Liu Jun Zi Tang was the most frequently prescribed TCM formula product, followed by Yu Ping Feng San and Zuo Gui Wan. The top three most commonly used TCM single products for adult leukemia patients were as follows, from the most common to the least:Radix Astragali membranaceus, Radix et Rhizoma Salviae miltiorrhizae, andFructus Ligustri Lucidi. Moreover, the top three most commonly prescribed TCM single products were Gui Pi Tang, Liu Wei Di Huang Wan, and Zuo Gui Wan.Table 5
Top ten formula CHPs and single CHPs prescribed by TCM physicians to treat pediatric and adult patients with leukemia in Taiwan, 2000–2011.
Single CHPs Formula CHPs Name Number, frequency (%) Name Number, frequency (%) Pediatric Radix Astragali membranaceus 103 (5.80) Xiang Sha Liu Jun Zi Tang 36 (7.86) Bulbus Fritillariae thunbergii 87 (4.90) Yu Ping Feng San 27 (5.90) Herba Hedyotis diffusa 74 (4.16) Zuo Gui Wan 25 (5.46) Radix Scutellariae baicalensis 65 (3.66) Bu Zhong Yi Qi Tang 24 (5.24) Radix Puerariae lobatae 57 (3.21) Shen Ling Bai Zhu San 20 (4.37) Radix Glycyrrhizae uralensis 52 (2.93) Bao He Wan 18 (3.93) Herba Houttuyniae cordata 45 (2.53) Xin Yi San 16 (3.49) Semen Ziziphi Spinosi 34 (1.91) Ma Zi Ren Wan 16 (3.49) Rhizoma Polygonati odorati 32 (1.80) Liu Wei Di Huang Wan 14 (3.06) Herba Scutellariae barbatae 29 (1.63) Ge Gen Tang 14 (3.06)  Adult Radix Astragali membranaceus 173 (4.07) Gui Pi Tang 83 (6.18) Radix et Rhizoma Salviae miltiorrhizae 133 (3.13) Liu Wei Di Huang Wan 53 (3.95) Fructus Ligustri Lucidi 108 (2.54) Zuo Gui Wan 39 (2.91) Sargentodoxa Cuneata 86 (2.02) Gui Lu Er Xian Jiao 39 (2.91) Herba Hedyotis diffusa 82 (1.93) Sheng Mai San 36 (2.68) Rhizoma Dioscoreae polystachya 71 (1.67) Jia Wei Xiao Yao San 35 (2.61) Bulbus Fritillaria thunbergii 69 (1.62) Xue Fu Zhu Yu Tang 27 (2.01) Cortex Lycii Radicis 63 (1.48) Xiang Sha Liu Jun Zi Tang 26 (1.94) Radix Glycyrrhizae uralensis 59 (1.39) Xin Yi Qing Fei Tang 25 (1.86) Semen Ziziphi Spinosae 58 (1.36) Ren Shen Yang Rong Tang 24 (1.79) TCM: Traditional Chinese Medicine; CHPs: Chinese herb products.


### 3.6. Overall Survival

We found that the overall survival rate was higher in TCM users compared to TCM nonusers in both pediatric and adult patients with leukemia (bothp<0.001) (Figure 2). During the 10 years that we followed, both pediatric and adult patients with leukemia who were TCM users had near 10% higher survival probability in comparison to the corresponding group of TCM nonusers patients. To further examine whether the overall survival rates were influenced by the number of days taking TCM and number of OPD visits for TCM use, we categorized these two variables using their median values as cutoff points (Figures 3 and 4). We observed that the overall survival rates were significantly different in subgroups of number of days taking TCM and OPD visits for TCM use in both pediatric and adult patients with leukemia (all p<0.001). We observed a dose-response relationship among three subgroups of TCM use according to either patients with number of days taking TCM or number of OPD visits for TCM use. The highest overall survival rates were found in patients with high number of days taking TCM (≥42.5 for pediatric patients and ≥28 for adult patients), which were significantly higher than those with low number of days taking TCM (<42.5 for pediatric patients and <28 for adult patients) (p=0.0049 for pediatric patients and p<0.0001 for adult patients) and were also significantly higher than those who were TCM nonusers (both p<0.001 for pediatric and adult patients). The differences in overall survival curves were different between patients with low number of days taking TCM and TCM nonusers (p=0.0051 and <0.001 for pediatric and adult patients, resp.). Similarly, we observed significant pairwise differences in overall survival function among three subgroups of TCM use based on number of OPD visits.Figure 2
Kaplan-Meier curves of overall survival in patients with leukemia based on TCM use during the follow-up period.
(a)
Pediatric (b)
AdultFigure 3
Kaplan-Meier curves of overall survival in patients with leukemia based on number of drug days for TCM use during the follow-up period. (a) TCM nonusers versus TCM user: days taking TCM < 42.5,p=0.0051. TCM nonusers versus TCM user: days taking TCM ≥ 42.5, p<0.001. TCM user: days taking TCM < 42.5 versus TCM user: days taking TCM ≥ 42.5, p=0.0049. (b) TCM nonusers versus TCM user: days taking TCM < 28, p<0.001. TCM nonusers versus TCM user: days taking TCM, p<0.001. TCM user: days taking TCM < 28 versus TCM user: days taking TCM ≥ 28, p=0.0001.
(a)
Pediatric (b)
AdultFigure 4
Kaplan-Meier curves of overall survival in patients with leukemia based on number of outpatient department (OPD) visits for TCM use during the follow-up period. (a) TCM nonusers versus TCM user: OPD < 6,p=0.0075; TCM nonusers versus TCM user: OPD ≥ 6, p<0.001; TCM user: OPD < 42.5 versus TCM user: OPD ≥ 6, p=0.0009. (b) TCM nonusers versus TCM user: OPD < 3, p<0.001; TCM nonusers versus TCM user: OPD ≥ 3, p<0.001; TCM user: OPD < 3 versus TCM user: OPD ≥ 3, p<0.001.
(a)
Pediatric (b)
Adult


## 3.1. Factors Associated with TCM Use

A total of 292 (12.40%) pediatric patients and 936 (9.17%) adult patients availed TCM outpatient services. In these leukemia patients, we observed that patients who were TCM users one year prior to the leukemia diagnosis and who resided in central area were more likely to utilize TCM services (Table1). The mean numbers of days taking TCM in pediatric and adult leukemia patients were 184 (SD = 328) days and 107 (SD = 254) days, respectively. The mean outpatient department (OPD) visits for TCM in pediatric and adult leukemia patients were 20.3 (SD = 35.3) and 10.5 (SD = 22.8), respectively. The distributions of cancer type were similar between TCM users and nonusers in both pediatric and adult leukemia patients.Table 1
Sociodemographic factors of pediatric and adult patients with leukemia according to use of TCM.
Characteristic ⁢Pediatric (N=2,355) ⁢Adult (N=10,208) TCM users TCM nonusers Adjusted OR‡ (95% CI) TCM users TCM nonusers Adjusted OR‡ (95% CI) N % N % N % N % Number of patients 292  2,063   936  9,272 Age, years 0–6 139 47.60 1,016 49.25 1.00 7–12 89 30.48 480 23.27 1.10 (0.81–1.50) 13–18 64 21.92 567 27.48 0.64 (0.46–0.89)∗∗ 19–40      274 29.27 2,199 23.72 1.00 41–60      379 40.38 3,012 32.48 0.95 (0.80–1.13) 61–80      284 30.34 4,061 43.80 0.60 (0.48–0.70)∗∗∗ Means (SD) 8.03 (5.07) 8.41 (5.65)  51.26 (15.67) 55.39 (17.24) Gender Female 129 44.18 843 40.86 1.00 428 45.73 3,740 40.34 1.00 Male 163 55.82 1,220 59.14 0.83 (0.64–1.07) 508 54.27 5,532 59.66 0.86 (0.74–0.99)∗ TCM use one year prior to leukemia diagnosis TCM nonusers 180 61.64 1,523 73.82 1.00 437 46.69 6,048 65.23 1.00 TCM users 112 38.36 540 26.18 1.62 (1.23–2.13)∗∗∗ 499 53.31 3,224 34.77 1.97 (1.71–2.26)∗∗∗ Insured amount (NT$/month) <20,000 286 97.95 2,035 98.64 1.00 610 65.17 6,736 72.65 1.00 20,000–39,999 6 2.05 27 1.31 2.02 (0.79–5.15) 197 21.05 1,613 17.40 1.23 (1.02–1.47)∗ 40,000–59,999 0 0.00 1 0.05 — 101 10.79 735 7.93 1.48 (1.15–1.90)∗∗ ≥60,000 — — — — — 28 2.99 188 2.03 1.65 (1.08–2.55)∗ Urbanization Level 1 (highest) 78 26.71 564 27.34 1.00 278 29.70 2,521 27.19 1.00 Level 2 97 33.22 655 31.75 0.85 (0.59–1.24) 279 29.81 2,698 29.10 0.86 (0.70–1.04) Level 3 48 16.44 371 17.98 0.52 (0.32–0.82)∗∗ 149 15.92 1,625 17.53 0.67 (0.53–0.85)∗∗∗ Level 4 45 15.41 296 14.35 0.63 (0.39–1.02) 134 14.32 1,329 14.34 0.74 (0.58–0.96)∗ Level 5 (lowest) 24 8.22 177 8.58 0.63 (0.34–1.14) 96 10.26 1,098 11.84 0.69 (0.51–0.94)∗ Residential area Northern 32 10.96 304 14.74 1.00 85 9.08 1,245 13.43 1.00 Taipei 75 25.68 750 36.35 0.76 (0.46–1.24) 274 29.27 229 34.83 1.01 (0.77–1.34) Central 104 35.62 306 14.83 3.33 (2.12–5.23)∗∗∗ 265 28.31 1,623 17.51 2.41 (1.85–3.14)∗∗∗ Southern 36 12.33 324 15.71 1.17 (0.69–1.99) 163 17.41 1,372 14.80 1.95 (1.47–2.59)∗∗∗ Eastern 3 1.03 42 2.04 0.73 (0.21–2.58) 27 2.88 261 2.82 1.78 (1.11–2.84)∗ Kao-Ping 42 14.38 337 16.34 1.16 (0.70–1.92) 122 13.03 1,541 16.62 1.13 (0.84–1.52) Insured unit Government, school employees 39 13.59 176 9.30 1.00 130 13.92 1,056 11.42 1.00 Private enterprise employees 145 50.52 916 48.39 0.70 (0.47–1.05) 404 43.25 3,533 38.21 0.91 (0.73–1.13) Occupational member 37 12.89 342 18.07 0.47 (0.28–0.77)∗∗ 198 21.20 1,973 21.34 0.87 (0.68–1.12) Farmers, fishermen 36 12.54 226 11.94 0.69 (0.40–1.18) 141 15.10 1,827 19.76 0.80 (0.60–1.07) Low-income households and veterans registered in local government agency 30 10.45 233 12.31 0.58 (0.34–0.98) 61 6.53 857 9.27 0.73 (0.52–1.02) Number of days taking TCM, means (SD) 184 (328) — —  107 (254) — — OPD visits for TCM, means (SD) 20.3 (35.3) — —  10.5 (22.8) — — Cancer subtype Lymphoid leukemia 205 70.21 1,377 66.75 1.00 217 23.18 1,896 20.45 1.00 Myeloid leukemia 79 27.05 609 29.52 1.10 (0.83–1.44) 649 69.34 6,670 71.94 0.85 (0.72–1.00) Uncertain 8 2.74 77 3.73 0.88 (0.42–1.85) 70 7.48 706 7.61 0.87 (0.65–1.15) ICD-9-CM: lymphoid leukemia, 204.xx; myeloid leukemia, 205.xx. TCM: Traditional Chinese Medicine; OR: odd ratio; SD: standard deviation; CI: confidence interval; OPD: outpatient department. ⁢p∗<0.05, p∗∗<0.01, and p∗∗∗<0.001. ‡Adjusted ORs were from the model considering age, gender, visit one year ago, insured amount, urbanization, residential area, and insured unit.


## 3.2. Medical Institutes

TCM users within pediatric leukemia patients engaged private hospitals more often for outpatient services than TCM pediatric nonusers (42.15% versus 38.70%). Similar trend was also seen within adult leukemia patients (36.17% versus 34.20%). On the contrary, private clinics were more often engaged for outpatient services by TCM nonusers of pediatric patients when compared to TCM users (41.37% versus 35.22%) as well as by TCM adult nonusers (43.32% versus 41.13%) (Table2).Table 2
Distributions of outpatient service providers for pediatric and adult patients with leukemia during 2001–2011.
Outpatient services providers TCM users TCM nonusers p value for χ2 Visits Percentage (95% CI) Visits Percentage (95% CI) Pediatric Type of provider     <0.001 Public hospitals 20,407 22.33 (22.06, 22.6) 80,522 19.47 (19.35, 19.59) Public Chinese medicine hospitals 20 0.02 (0.01, 0.03) 92 0.02 (0.02, 0.03) Private hospitals 38,522 42.15 (41.83, 42.47) 160,049 38.70 (38.55, 38.85) Private Chinese medicine hospitals 86 0.09 (0.07, 0.11) 191 0.05 (0.04, 0.05) Public clinics 160 0.18 (0.15, 0.2) 1,497 0.36 (0.34, 0.38) Private clinics 32,187 35.22 (34.91, 35.53) 171,108 41.37 (41.22, 41.52) Other medicine service providers 9 0.01 (0, 0.02) 103 0.02 (0.02, 0.03)  Total 91,391  413,562  Adult Type of provider     <0.001 Public hospitals 52,167 20.64 (20.49, 20.80) 354,202 19.77 (19.71, 19.83) Public Chinese medicine hospitals 400 0.16 (0.14, 0.17) 905 0.05 (0.05, 0.05) Private hospitals 91,396 36.17 (35.98, 36.36) 612,655 34.20 (34.13, 34.27) Private Chinese medicine hospitals 614 0.24 (0.22, 0.26) 4,044 0.23 (0.22, 0.23) Public clinics 3,782 1.5 (1.45, 1.54) 40,716 2.27 (2.25, 2.29) Private clinics 103,932 41.13 (40.94, 41.32) 776,052 43.32 (43.24, 43.39) Other medicine service providers 399 0.16 (0.14, 0.17) 3,026 0.17 (0.16, 0.17)  Total 252,690  1,791,600 TCM: Traditional Chinese Medicine; CI: confidence interval.


## 3.3. Coexisting Diseases

We observed that lymphoid leukemia and myeloid leukemia were the two major diagnoses in these leukemia patients. Lymphoid leukemia was common in children and myeloid leukemia was diagnosed mainly in adults. Acute upper and lower respiratory infections were commonly diagnosed in both pediatric and adult patients, irrespective of TCM use by the patients (Table3).Table 3
Top 5 disease codes among pediatric and adult leukemia patients during the years 2001–2011 for all outpatients visits.
Ranking TCM users TCM nonusers Disease (Code) Number Percentage (95% CI) Disease (Code) Number Percentage (95% CI) Pediatric Total visits 91,391   413,562 1 Lymphoid leukemia (204) 36,529 39.97 (39.65, 40.29) Lymphoid leukemia (204) 138,518 33.49 (33.35, 33.64) 2 Myeloid leukemia (205) 7,801 8.54 (8.35, 8.72) Acute upper respiratory infections (465) 45,756 11.06 (10.97, 11.16) 3 Acute upper respiratory infections (465) 6,873 7.52 (7.35, 7.69) Myeloid leukemia (205) 34,551 8.35 (8.27, 8.44) 4 Leukemia of unspecified cell type (208) 4,698 5.14 (5, 5.28) Acute bronchitis and bronchiolitis (466) 15,506 3.75 (3.69, 3.81) 5 Acute bronchitis and bronchiolitis (466) 2,962 3.24 (3.13, 3.36) Acute sinusitis (461) 12,141 2.94 (2.88, 2.99)  Adult Total visits 252,690   1,791,600 1 Myeloid leukemia (205) 55,031 21.78 (21.62, 21.94) Myeloid leukemia (205) 264,653 14.77 (14.72, 14.82) 2 Lymphoid leukemia (204) 19,336 7.65 (7.55, 7.76) Acute upper respiratory infections (465) 97,491 5.44 (5.41, 5.47) 3 Acute upper respiratory infections (465) 11,117 4.4 (4.32, 4.48) Lymphoid leukemia (204) 76,117 4.25 (4.22, 4.28) 4 Gingival and periodontal diseases (523) 5,680 2.25 (2.19, 2.31) Diabetes mellitus (250) 56,042 3.13 (3.1, 3.15) 5 Diseases of hard tissues of teeth (521) 5,123 2.03 (1.97, 2.08) Essential hypertension (401) 53,009 2.96 (2.93, 2.98) TCM: Traditional Chinese Medicine; CI: confidence interval.


## 3.4. Expenditures

According to our analysis, drug fee was the major component of all outpatient medical expenditures (Table4). For both pediatric and adult leukemia patients, the average cost of total amount per visit was higher for TCM users than that of TCM nonusers. In adult leukemia patients, the average cost of drug fee per visit in TCM users was higher than that of TCM nonusers. Nevertheless, the differences in average costs between these two groups were indeed minimal (2,557.98 NT$ versus 2,535.07 NT$). The costs of other items per visit in TCM users in adult leukemia patients were significantly lower than those of TCM nonusers, including fees for consultation, treatment, medical supply, and diagnosis fee. In pediatric patients, the average cost per visit in TCM users was consistently higher than that of TCM nonusers for all items including fees for consultation, treatment, medical supply, diagnosis fee, and drug fee.Table 4
Expenditures for outpatient services for pediatric and adult leukemia patients (NT$) during the period 2001–2011.
Characteristic TCM users TCM nonusers t value Total Percentage(95% CI) Average cost per visit(95% CI) Total Percentage(95% CI) Average cost per visit(95% CI) Pediatric Outpatient visits 91,391   413,562 Fees for consultation, treatment, and medical supplies 52,088,100 38.09 (38.08, 38.1) 569.95 (559.62, 580.28) 245,838,958 32.74 (32.73, 32.74) 594.45 (589.71, 599.19) 4.22 ∗ ∗ ∗ Diagnosis fee 19,341,052 14.14 (14.14, 14.15) 211.63 (210.86, 212.4) 88,180,707 11.74 (11.74, 11.74) 213.22 (212.84, 213.61) 3.64 ∗ ∗ ∗ Drug fee 65,311,809 47.76 (47.75, 47.77) 714.64 (680.14, 749.15) 416,969,010 55.52 (55.52, 55.53) 1008.25 (986.8, 1029.7) 14.16 ∗ ∗ ∗ Total amount 136,740,961 100 1496.22 (1459.61, 1532.83) 750,988,675 100 1815.92 (1793.74, 1838.1) 14.64 ∗ ∗ ∗  Adult Outpatient visits 252,690   1,791,600 Fees for consultation, treatment, and medical supplies 170,260,064 19.55 (19.55, 19.56) 673.79 (663.88, 683.70) 1,282,955,508 20.66 (20.66, 20.66) 716.10 (711.68, 720.52) 7.64 ∗ ∗ ∗ Diagnosis fee 54,059,202 6.21 (6.21, 6.21) 213.93 (213.46, 214.41) 386,270,204 6.22 (6.22, 6.22) 215.60 (215.42, 215.78) 6.46 ∗ ∗ ∗ Drug fee 646,375,253 74.24 (74.23, 74.24) 2557.98 (2512.05, 2603.91) 4,541,817,387 73.12 (73.12, 73.13) 2535.07 (2516.85, 2553.29) −0.91 Total amount 870,694,519 100 3445.70 (3398.59, 3492.81) 6,211,043,099 100 3466.77 (3447.99, 3485.55) 0.81 p   ∗ ∗ ∗ < 0.001.


## 3.5. Most Commonly Prescribed TCM Single and Formula Products

Details of the TCM single and formula products most frequently prescribed by TCM physicians are shown in Table5. In pediatric leukemia patients,Radix Astragali membranaceus was the most commonly prescribed TCM single product, followed byBulbus Fritillariae thunbergii, andHerba Hedyotis diffusa. Moreover, Xiang Sha Liu Jun Zi Tang was the most frequently prescribed TCM formula product, followed by Yu Ping Feng San and Zuo Gui Wan. The top three most commonly used TCM single products for adult leukemia patients were as follows, from the most common to the least:Radix Astragali membranaceus, Radix et Rhizoma Salviae miltiorrhizae, andFructus Ligustri Lucidi. Moreover, the top three most commonly prescribed TCM single products were Gui Pi Tang, Liu Wei Di Huang Wan, and Zuo Gui Wan.Table 5
Top ten formula CHPs and single CHPs prescribed by TCM physicians to treat pediatric and adult patients with leukemia in Taiwan, 2000–2011.
Single CHPs Formula CHPs Name Number, frequency (%) Name Number, frequency (%) Pediatric Radix Astragali membranaceus 103 (5.80) Xiang Sha Liu Jun Zi Tang 36 (7.86) Bulbus Fritillariae thunbergii 87 (4.90) Yu Ping Feng San 27 (5.90) Herba Hedyotis diffusa 74 (4.16) Zuo Gui Wan 25 (5.46) Radix Scutellariae baicalensis 65 (3.66) Bu Zhong Yi Qi Tang 24 (5.24) Radix Puerariae lobatae 57 (3.21) Shen Ling Bai Zhu San 20 (4.37) Radix Glycyrrhizae uralensis 52 (2.93) Bao He Wan 18 (3.93) Herba Houttuyniae cordata 45 (2.53) Xin Yi San 16 (3.49) Semen Ziziphi Spinosi 34 (1.91) Ma Zi Ren Wan 16 (3.49) Rhizoma Polygonati odorati 32 (1.80) Liu Wei Di Huang Wan 14 (3.06) Herba Scutellariae barbatae 29 (1.63) Ge Gen Tang 14 (3.06)  Adult Radix Astragali membranaceus 173 (4.07) Gui Pi Tang 83 (6.18) Radix et Rhizoma Salviae miltiorrhizae 133 (3.13) Liu Wei Di Huang Wan 53 (3.95) Fructus Ligustri Lucidi 108 (2.54) Zuo Gui Wan 39 (2.91) Sargentodoxa Cuneata 86 (2.02) Gui Lu Er Xian Jiao 39 (2.91) Herba Hedyotis diffusa 82 (1.93) Sheng Mai San 36 (2.68) Rhizoma Dioscoreae polystachya 71 (1.67) Jia Wei Xiao Yao San 35 (2.61) Bulbus Fritillaria thunbergii 69 (1.62) Xue Fu Zhu Yu Tang 27 (2.01) Cortex Lycii Radicis 63 (1.48) Xiang Sha Liu Jun Zi Tang 26 (1.94) Radix Glycyrrhizae uralensis 59 (1.39) Xin Yi Qing Fei Tang 25 (1.86) Semen Ziziphi Spinosae 58 (1.36) Ren Shen Yang Rong Tang 24 (1.79) TCM: Traditional Chinese Medicine; CHPs: Chinese herb products.


## 3.6. Overall Survival

We found that the overall survival rate was higher in TCM users compared to TCM nonusers in both pediatric and adult patients with leukemia (bothp<0.001) (Figure 2). During the 10 years that we followed, both pediatric and adult patients with leukemia who were TCM users had near 10% higher survival probability in comparison to the corresponding group of TCM nonusers patients. To further examine whether the overall survival rates were influenced by the number of days taking TCM and number of OPD visits for TCM use, we categorized these two variables using their median values as cutoff points (Figures 3 and 4). We observed that the overall survival rates were significantly different in subgroups of number of days taking TCM and OPD visits for TCM use in both pediatric and adult patients with leukemia (all p<0.001). We observed a dose-response relationship among three subgroups of TCM use according to either patients with number of days taking TCM or number of OPD visits for TCM use. The highest overall survival rates were found in patients with high number of days taking TCM (≥42.5 for pediatric patients and ≥28 for adult patients), which were significantly higher than those with low number of days taking TCM (<42.5 for pediatric patients and <28 for adult patients) (p=0.0049 for pediatric patients and p<0.0001 for adult patients) and were also significantly higher than those who were TCM nonusers (both p<0.001 for pediatric and adult patients). The differences in overall survival curves were different between patients with low number of days taking TCM and TCM nonusers (p=0.0051 and <0.001 for pediatric and adult patients, resp.). Similarly, we observed significant pairwise differences in overall survival function among three subgroups of TCM use based on number of OPD visits.Figure 2
Kaplan-Meier curves of overall survival in patients with leukemia based on TCM use during the follow-up period.
(a)
Pediatric (b)
AdultFigure 3
Kaplan-Meier curves of overall survival in patients with leukemia based on number of drug days for TCM use during the follow-up period. (a) TCM nonusers versus TCM user: days taking TCM < 42.5,p=0.0051. TCM nonusers versus TCM user: days taking TCM ≥ 42.5, p<0.001. TCM user: days taking TCM < 42.5 versus TCM user: days taking TCM ≥ 42.5, p=0.0049. (b) TCM nonusers versus TCM user: days taking TCM < 28, p<0.001. TCM nonusers versus TCM user: days taking TCM, p<0.001. TCM user: days taking TCM < 28 versus TCM user: days taking TCM ≥ 28, p=0.0001.
(a)
Pediatric (b)
AdultFigure 4
Kaplan-Meier curves of overall survival in patients with leukemia based on number of outpatient department (OPD) visits for TCM use during the follow-up period. (a) TCM nonusers versus TCM user: OPD < 6,p=0.0075; TCM nonusers versus TCM user: OPD ≥ 6, p<0.001; TCM user: OPD < 42.5 versus TCM user: OPD ≥ 6, p=0.0009. (b) TCM nonusers versus TCM user: OPD < 3, p<0.001; TCM nonusers versus TCM user: OPD ≥ 3, p<0.001; TCM user: OPD < 3 versus TCM user: OPD ≥ 3, p<0.001.
(a)
Pediatric (b)
Adult


## 4. Discussion

This study investigated the potential of TCM use as an adjuvant therapy for leukemia patients, both pediatric and adult, in Taiwan undergoing treatment with WM. The determinants for TCM utilization for leukemia patients in Taiwan, such as medical expenditure, and therapeutic effects were only scarcely reported in the past [18]. Our study shows that the combination therapy using TCM and WM for patients with leukemia does not cause additional financial burden relative to using WM only. Importantly, TCM use is associated with longer survival.We observed that TCM utilization was more prevalent in pediatric leukemia patients rather than adults. We assume that children can barely tolerate the extremely uncomfortable symptoms and feelings accompanying chemotherapy, as previously suggested [19]. Studies show that TCM can alleviate adverse effects of WM and improve quality of life in cancer patients [7, 10, 11, 13]. Andersen’s health behavior model, which is advocated by many scholars of sociology and public health, claims that the use of health services is determined by predisposing factors, enabling factors, and need factors [20]. In our study, significant factors for TCM use included predisposing factors of gender and health beliefs, such as TCM use one year prior to leukemia diagnosis. Enabling factors observed were height of medical insurance, residential area, and urbanization level, which were similar to those reported by Liao et al. [21, 22]. On the other hand, a particularly higher prevalence of TCM utilization was observed in central Taiwan, which has the highest per capita ratio of TCM physicians.Radix Astragali membranaceus andFructus Ligustri Lucidi were in the top 3 herbs for adult users andRadix Astragali membranaceus was the top one herbs for pediatric users. Both of these herbs have a function that increases white blood cell count [23]. Due to the indication of leukemia being a consistently elevated white blood cell count, some physicians thought using the herbs that increase white blood cell count is not recommended because of the potential exacerbation of leukemia. Given the findings of the present study, these herbs may increase healthy WBC without aggravating the leukemia. This can be supported by the prior studies of these two herbs demonstrating that they bolster host immune response for cytotoxic activity by promoting apoptosis of tumor cells and may help the recovery from chemotherapy or radiation treatments [18, 24–27]. The findings of the present study provide important information for TCM physicians and patients with leukemia.The National Health Insurance program was started on March 1, 1995. In 2011, 22.60 million out of 22.96 million Taiwan residents were enrolled in this program. The comprehensive NHI database is considered an appropriate source to assess certain diseases. In addition, the NHI database provides abundant sample population size and details in studies, eliminating the bias associated with a limited sample size.Our study has several limitations, though. Firstly, some patients visiting TCM physicians preferred to receive decoction formulations of Chinese medicine, which were self-paid and not covered by the NHI program. In addition, about 10% of the TCM clinics were not contracted to the NHI because of the low reimbursement rates provided by the NHI. Therefore, the prevalence of TCM use and costs of outpatient visits could be underestimated. Secondly, we only explored the efficacy of general TCM utilization, including overall survival, but we did not consider the subtypes of leukemia and TCM prescriptions, which should be investigated in further studies. Last, the database does not contain information on daily activity, dietary habits, and body mass index, which may also be factors for TCM utilization and health care costs. Further studies considering the above information are therefore warranted.


## 5. Conclusion

Our study investigated the TCM utilization and prevalence among pediatric and adult patients with leukemia in Taiwan. It shows that TCM as adjuvant therapy combined with WM may indeed alleviate adverse symptoms, improve quality of life, and prolong overall survival, without incurring excess medical expenditure. This line of study in the future should aim at ruling out the possible confounders such as diet, lifestyle behaviors of exercise, and psychological status. The results of our study could be useful to health-policy decision makers as well as clinical practitioners while considering the integration of TCM with WM.



---

*Source: 8394850-2016-10-25.xml*